Nucleic Acid Nanoparticles for Treating Human Diseases
A noninvasive avenue for Parkinson's disease
Wipo Publishes Patent of
Northeastern University and Copernicus Therapeutics for "Methods for
Delivery to the Central Nervous System of Nucleic Acid Nanoparticles to Treat
Central Nervous System Disorders"
Foundation Fighting Blindness invests $8.25 million in
gene therapy research
Copernicus to Further
Development of Non-Viral Gene Therapy for Parkinson’s Disease
Case Western Reserve University with Copernicus Therapeutics and Polgenix Receive $3.9 Million from the Ohio
Biomedical Research Commercialization Program (BRCP)
Copernicus Receives Milestone Payment from Cystic Fibrosis Foundation Therapeutics to Further Development of its Non-Viral Gene Therapy for Cystic Fibrosis.
Copernicus’ Nanoparticle Technology Applied to siRNA.
Vision Deficit in Retinitis Pigmentosa Mice Corrected with DNA.
Copernicus to Receive Increased Support from Cystic Fibrosis Foundation Therapeutics to Further Development of its Non-Viral Gene Therapy for Cystic Fibrosis.
Copernicus Demonstrates Ability of its Non-Viral Delivery System to Efficiently Transfer Large Sizes of Nucleic Acids into Lung Cells.